Chetasi Talati

2.0k total citations
78 papers, 1.1k citations indexed

About

Chetasi Talati is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Chetasi Talati has authored 78 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Hematology, 42 papers in Genetics and 17 papers in Molecular Biology. Recurrent topics in Chetasi Talati's work include Acute Myeloid Leukemia Research (58 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (31 papers) and Chronic Myeloid Leukemia Treatments (28 papers). Chetasi Talati is often cited by papers focused on Acute Myeloid Leukemia Research (58 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (31 papers) and Chronic Myeloid Leukemia Treatments (28 papers). Chetasi Talati collaborates with scholars based in United States, Australia and Germany. Chetasi Talati's co-authors include Richard D. Kim, Dae Won Kim, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman, Javier Pinilla‐Ibarz, Eric Padron, Rami S. Komrokji, Alan F. List and Andrew Kuykendall and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chetasi Talati

72 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chetasi Talati United States 16 592 512 326 247 157 78 1.1k
Michal Bar‐Natan United States 15 719 1.2× 524 1.0× 364 1.1× 312 1.3× 114 0.7× 41 1.3k
Maria Kleppe United States 13 361 0.6× 459 0.9× 302 0.9× 230 0.9× 128 0.8× 24 947
Elisabeth Oppliger Leibundgut Switzerland 16 412 0.7× 480 0.9× 311 1.0× 178 0.7× 60 0.4× 38 897
Devendra Hiwase Australia 20 944 1.6× 378 0.7× 489 1.5× 296 1.2× 92 0.6× 107 1.3k
Yosuke Minami Japan 22 812 1.4× 802 1.6× 355 1.1× 395 1.6× 148 0.9× 103 1.6k
S. Faderl United States 16 882 1.5× 417 0.8× 393 1.2× 240 1.0× 64 0.4× 24 1.2k
Mateusz Koptyra United States 15 597 1.0× 424 0.8× 349 1.1× 157 0.6× 72 0.5× 35 958
Hankui Chen United States 12 423 0.7× 506 1.0× 152 0.5× 147 0.6× 257 1.6× 22 993
Bertil Uggla Sweden 14 600 1.0× 485 0.9× 195 0.6× 414 1.7× 123 0.8× 31 1.1k
Francesca Arruga Italy 20 394 0.7× 502 1.0× 550 1.7× 312 1.3× 149 0.9× 60 1.3k

Countries citing papers authored by Chetasi Talati

Since Specialization
Citations

This map shows the geographic impact of Chetasi Talati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chetasi Talati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chetasi Talati more than expected).

Fields of papers citing papers by Chetasi Talati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chetasi Talati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chetasi Talati. The network helps show where Chetasi Talati may publish in the future.

Co-authorship network of co-authors of Chetasi Talati

This figure shows the co-authorship network connecting the top 25 collaborators of Chetasi Talati. A scholar is included among the top collaborators of Chetasi Talati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chetasi Talati. Chetasi Talati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Voorhees, Peter M., Anita D’Souza, Alfred Chung, et al.. (2024). Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7531–7531. 8 indexed citations
2.
Mangaonkar, Abhishek A., Terra L. Lasho, Rhett P. Ketterling, et al.. (2022). Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal. 12(2). 26–26. 11 indexed citations
3.
Saygin, Caner, Gregory W. Roloff, Christopher N Hahn, et al.. (2022). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances. 7(4). 549–554. 23 indexed citations
4.
Sallman, David A., Hany Elmariah, Kendra Sweet, et al.. (2021). Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. Blood. 138(Supplement 1). 825–825. 21 indexed citations
5.
Mangaonkar, Abhishek A., Terra L. Lasho, Christy M. Finke, et al.. (2021). Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia. 35(11). 3329–3333. 2 indexed citations
6.
Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2020). Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research. 93. 106367–106367. 13 indexed citations
7.
Ali, Najla Al, Onyee Chan, David A. Sallman, et al.. (2020). Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clinical Lymphoma Myeloma & Leukemia. 21(1). e52–e56. 1 indexed citations
8.
Talati, Chetasi, David A. Sallman, Seongseok Yun, et al.. (2020). Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis. Blood. 136(Supplement 1). 37–37. 1 indexed citations
9.
Talati, Chetasi, et al.. (2020). Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. Current Opinion in Hematology. 27(2). 66–75. 6 indexed citations
10.
Kuykendall, Andrew, David A. Sallman, Najla Al Ali, et al.. (2019). Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clinical Lymphoma Myeloma & Leukemia. 20(5). 312–315. 3 indexed citations
11.
Goldberg, Aaron D., Chetasi Talati, Pinkal Desai, et al.. (2018). TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 1433–1433. 35 indexed citations
12.
Talati, Chetasi, David A. Sallman, & Alan F. List. (2018). SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clinical Lymphoma Myeloma & Leukemia. 18(10). 629–635. 4 indexed citations
13.
Knepper, Todd C., Yehuda E. Deutsch, Justin M. Watts, et al.. (2018). Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia. Blood. 132(Supplement 1). 1524–1524. 2 indexed citations
14.
Kuykendall, Andrew, Chetasi Talati, Najla Al Ali, et al.. (2017). Gaining a Better Sense for ASXL1 Mutations in Myelofibrosis: Assessing the Variable Impact of Frameshift, Nonsense, and Missense Mutations. Blood. 130. 2939–2939.
15.
Talati, Chetasi, Andrew Kuykendall, Najla Al Ali, et al.. (2017). Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype. Blood. 130. 1412–1412. 1 indexed citations
16.
Kuykendall, Andrew, Chetasi Talati, Pearlie K. Epling‐Burnette, et al.. (2017). Relative Lymphocytosis Is Associated with Improved Outcome in Myelofibrosis and May Account for the Favorable Prognosis of the Calr mutation. Blood. 130. 1634–1634. 2 indexed citations
17.
Kim, Dae Won, Chetasi Talati, & Richard D. Kim. (2017). Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy. Journal of Gastrointestinal Oncology. 8(2). 256–265. 255 indexed citations
18.
Talati, Chetasi & Eric Padron. (2016). An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Current Hematologic Malignancy Reports. 11(6). 425–433. 15 indexed citations
19.
Talati, Chetasi, Elizabeth A. Griffiths, Meir Wetzler, & Eunice S. Wang. (2015). Polo-like kinase inhibitors in hematologic malignancies. Critical Reviews in Oncology/Hematology. 98. 200–210. 25 indexed citations
20.
Talati, Chetasi, et al.. (2014). How we will treat chronic myeloid leukemia in 2016. Blood Reviews. 29(2). 137–142. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michal Bar‐Natan Breakdown of academic impact, for papers by Maria Kleppe Breakdown of academic impact, for papers by Elisabeth Oppliger Leibundgut Breakdown of academic impact, for papers by Devendra Hiwase Breakdown of academic impact, for papers by Yosuke Minami Breakdown of academic impact, for papers by S. Faderl Breakdown of academic impact, for papers by Mateusz Koptyra Breakdown of academic impact, for papers by Hankui Chen Breakdown of academic impact, for papers by Bertil Uggla Breakdown of academic impact, for papers by Francesca Arruga
Rankless by CCL
2026